Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
Wake Forest University Health Sciences
Kestrel Therapeutics, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Avera McKennan Hospital & University Health Center
Imperial College London
Institut Paoli-Calmettes
Mayo Clinic
Mayo Clinic
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Brigham and Women's Hospital
Kaiser Permanente
Duke University
Dana-Farber Cancer Institute
University of Nebraska
University of Oklahoma
M.D. Anderson Cancer Center
Medical College of Wisconsin
Mayo Clinic
RenJi Hospital
Cancer Research UK
West China Hospital
UNC Lineberger Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
University of British Columbia
Vanderbilt-Ingram Cancer Center
EtiraRx Australia Pty Ltd
Weill Medical College of Cornell University
Cancer Research UK
University of California, San Francisco
NuCana plc
University of Alabama at Birmingham
UNICANCER
Esperas Pharma Inc.
WellSpan Health
University of South Florida
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Universidade Federal de Pernambuco
San Raffaele University
Vall d'Hebron Institute of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Comprehensive Support Project for Oncology Research
Jules Bordet Institute
Universitair Ziekenhuis Brussel
Institut de cancérologie Strasbourg Europe